Inhibrx Biosciences (INBX) - Quarterly EPS earnings growth

Official company branding of Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences (INBX) business is shielded from macroeconomic downturns, as demand for oncology drugs remains stable. However, stringent FDA oversight and costly clinical trials create significant barriers to entry. This quarterly EPS chart, where the -8.00 parameter determines the metric's value, confirms a high level of scientific confidence in the company's assets among major institutional investors.

Inhibrx Biosciences, Inc. (INBX) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for Inhibrx Biosciences

- market value and analyst target forecast:
Fundamental company analysis:inhibrx.com, INBX
Manufactured product of Inhibrx Corp

An issuer's long-term reliability is determined by the stability of its earnings per share generation. This indicator tracks the daily dynamics of quarterly EPS changes, excluding temporary data gaps. By analyzing the quarterly growth slice of EPS, an investor sees the current value of -8.00, which allows for the timely recognition of a value trap. For Inhibrx Biosciences (INBX), given its lack of commercial products, such volatility confirms a dependence on external financing.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|IMAB - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Year-over-year earnings per share growth for the last twelve months|NVCT - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months coherus.com|CRBP: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Cardiff Oncology, Inc. CRDF|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (aprea.com)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc